CN103992405B - 抗-vegf抗体 - Google Patents

抗-vegf抗体 Download PDF

Info

Publication number
CN103992405B
CN103992405B CN201410106341.7A CN201410106341A CN103992405B CN 103992405 B CN103992405 B CN 103992405B CN 201410106341 A CN201410106341 A CN 201410106341A CN 103992405 B CN103992405 B CN 103992405B
Authority
CN
China
Prior art keywords
antibody
amino acid
district
cell
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201410106341.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103992405A (zh
Inventor
柯耀煌
朱伟民
余国良
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yikang Co
Original Assignee
Yikang Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yikang Co filed Critical Yikang Co
Publication of CN103992405A publication Critical patent/CN103992405A/zh
Application granted granted Critical
Publication of CN103992405B publication Critical patent/CN103992405B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201410106341.7A 2008-03-26 2008-10-08 抗-vegf抗体 Active CN103992405B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3971908P 2008-03-26 2008-03-26
US61/039,719 2008-03-26
CN200880128968.5A CN102065888B (zh) 2008-03-26 2008-10-08 抗-vegf抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200880128968.5A Division CN102065888B (zh) 2008-03-26 2008-10-08 抗-vegf抗体

Publications (2)

Publication Number Publication Date
CN103992405A CN103992405A (zh) 2014-08-20
CN103992405B true CN103992405B (zh) 2016-08-17

Family

ID=41114205

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410106341.7A Active CN103992405B (zh) 2008-03-26 2008-10-08 抗-vegf抗体
CN200880128968.5A Active CN102065888B (zh) 2008-03-26 2008-10-08 抗-vegf抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200880128968.5A Active CN102065888B (zh) 2008-03-26 2008-10-08 抗-vegf抗体

Country Status (9)

Country Link
US (2) US7803371B2 (enExample)
EP (1) EP2259795B1 (enExample)
JP (2) JP5823858B2 (enExample)
KR (1) KR101581244B1 (enExample)
CN (2) CN103992405B (enExample)
AU (1) AU2008353479B2 (enExample)
BR (1) BRPI0822556B1 (enExample)
CA (3) CA2719400C (enExample)
WO (1) WO2009120178A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032894T2 (hu) * 2008-06-25 2017-11-28 Esbatech Alcon Biomed Res Unit VEGF-gátló, stabilis és oldható antitestek
CN102002104A (zh) * 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
CA2778084A1 (en) * 2009-10-23 2011-04-28 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using same
AU2012223449A1 (en) * 2011-03-03 2013-05-02 Apexigen, Inc. Anti-IL-6 receptor antibodies and methods of use
CN104650229A (zh) * 2011-11-02 2015-05-27 埃派斯进有限公司 抗-kdr抗体和使用方法
CN103417964A (zh) * 2012-05-17 2013-12-04 江苏先声药物研究有限公司 一种抗vegf抗体的用途
CN103417965B (zh) * 2012-05-17 2018-04-13 江苏先声药业有限公司 一种含有抗vegf抗体的药物组合物
SMT202000088T1 (it) 2013-02-18 2020-03-13 Vegenics Pty Ltd Molecole leganti ligandi e relativi usi
JP2016530244A (ja) * 2013-12-31 2016-09-29 ディベロップメント センター フォー バイオテクノロジーＤｅｖｅｌｏｐｍｅｎｔ Ｃｅｎｔｅｒ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ 抗ｖｅｇｆ抗体及びその使用
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
WO2016115521A1 (en) * 2015-01-16 2016-07-21 Alder Biopharmaceuticals, Inc. Anti-glycoprotein antibodies and uses thereof
TN2017000543A1 (en) * 2015-07-06 2019-04-12 Ucb Biopharma Sprl Tau-binding antibodies
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
MX2022002855A (es) * 2019-09-13 2022-06-02 Admare Therapeutics Soc Anticuerpos antiantígenos de virus oncolíticos y métodos de uso de los mismos.
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
CN120769866A (zh) * 2022-12-29 2025-10-10 Ltz治疗股份有限公司 抗CD79b抗体及其用途
CN118344476B (zh) * 2024-05-16 2024-11-15 武汉爱博泰克生物科技有限公司 人c反应蛋白单克隆抗体、抗体对和检测试剂或试剂盒及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1299833A (zh) * 1999-12-30 2001-06-20 华西医科大学口腔医学研究所 抗人血管内皮生长因子单链抗体及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2223705T3 (es) * 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
CA2492524A1 (en) * 2002-08-15 2004-02-26 Epitomics, Inc. Humanized rabbit antibodies
AU2003259718A1 (en) 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
CN104004094B (zh) * 2008-06-25 2017-09-22 艾斯巴技术-诺华有限责任公司 使用通用抗体构架进行的兔抗体的人源化
CN102002104A (zh) * 2009-08-28 2011-04-06 江苏先声药物研究有限公司 一种抗vegf的单克隆抗体及含有该抗体的药物组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1299833A (zh) * 1999-12-30 2001-06-20 华西医科大学口腔医学研究所 抗人血管内皮生长因子单链抗体及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
利用重组人VEGF165制备单克隆抗体的研究;孙大军等;《白求恩医科大学学报》;20010930;第27卷(第05期);摘要、第2.4节 *
抗人VEGF165单链抗体的构建与表达;赵泽国等;《免疫学杂志》;20000225;第16卷(第02期);摘要 *

Also Published As

Publication number Publication date
JP2014205674A (ja) 2014-10-30
CN102065888B (zh) 2014-03-26
CA2981887A1 (en) 2009-10-01
KR101581244B1 (ko) 2015-12-31
US20110008367A1 (en) 2011-01-13
US20090246190A1 (en) 2009-10-01
CA2981887C (en) 2019-09-03
CA2719400C (en) 2017-11-14
HK1201280A1 (en) 2015-08-28
US7803371B2 (en) 2010-09-28
AU2008353479A1 (en) 2009-10-01
WO2009120178A1 (en) 2009-10-01
JP2011517447A (ja) 2011-06-09
BRPI0822556B1 (pt) 2022-03-03
EP2259795A4 (en) 2012-06-06
CA3053675A1 (en) 2009-10-01
KR20100132983A (ko) 2010-12-20
AU2008353479B2 (en) 2014-02-20
CA2719400A1 (en) 2009-10-01
BRPI0822556A2 (pt) 2020-08-18
US8088375B2 (en) 2012-01-03
EP2259795A1 (en) 2010-12-15
JP5823858B2 (ja) 2015-11-25
CN102065888A (zh) 2011-05-18
EP2259795B1 (en) 2016-04-06
CN103992405A (zh) 2014-08-20

Similar Documents

Publication Publication Date Title
CN103992405B (zh) 抗-vegf抗体
CN102448987B (zh) 一种抗vegf的单克隆抗体及含有该抗体的药物组合物
CN111234020B (zh) 一种bcma结合蛋白及其制备方法和应用
CN107011434A (zh) 用于产生针对细胞相关抗原如p2x7、cxcr7或cxcr4的免疫球蛋白的基因免疫
CN116284375A (zh) 非pH依赖性长效型抗血清白蛋白纳米抗体及其应用
CN116589564B (zh) 抗aav5抗体及快速aav5滴度测定elisa试剂盒
IL303443A (en) A monoclonal antibody against LAG-3 and its antigen-binding fragment, and their use
US20230279127A1 (en) Il12 receptor synthetic cytokines and methods of use
KR20250173509A (ko) 클라우딘18.2에 특이적으로 결합하는 항체, 및 이의 제조 방법 및 이의 응용
CN104045713B (zh) 一种抗Blys的单克隆抗体及含有该抗体的药物组合物
CN119661721B (zh) 一种抗甘胆酸抗体及其应用
US20230272088A1 (en) Ifngr binding synthetic cytokines and methods of use
TWI698643B (zh) 用於檢測米田堡血型抗原的抗體及其片段、試劑盒及方法
CN117043192B (zh) 针对IL-13Rα2的抗体及其应用
CN117843776B (zh) 抗体分子、核酸、制药用途及炎性疾病治疗方法
AU2014202474B2 (en) Anti-VEGF antibody
TW202542189A (zh) Cfc1結合分子
HK1201280B (en) Anti-vegf antibody
HK40031847B (en) A bcma binding protein and method for preparation and application thereof
HK40031847A (en) A bcma binding protein and method for preparation and application thereof
CN109709337A (zh) 人cd26的免疫组化检测试剂盒及其临床应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1201280

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1201280

Country of ref document: HK